       Document 2837
 DOCN  M94A2837
 TI    Treatment of HIV infected adult patients with high-dose intravenous
       immunoglobulin. A randomized trial.
 DT    9412
 AU    Kiehl M; Heese C; Stoll R; Domschke W; Department of Internal Medicine
       A, University of Munster,; Germany.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):213 (abstract no. PB0282). Unique
       Identifier : AIDSLINE ICA10/94369738
 AB    HIV infected patient show a profound deficit of cellular and humoral
       immunity. This immunologic impairment causes a markedly increased
       incidence of serious recurrent infections with opportunistic and other
       microorganisms. Mostly, these infections are difficult to treat and
       require hospitalization. Intravenous immunoglobulin (IVIG) has been
       shown to reduce bacterial infections in HIV-infected children. In adults
       a similar therapeutic approach is still a matter of debate. Therefore we
       conduct a clinical trial of high dose intravenous immunoglobulin (0.4
       g/kg BW initially following 2 g/kg BW every 3 weeks; Venimmun,
       Behringwerke, Frankfurt, Germany) to study the effect on the frequency
       of hospitalization, body weight, fever and infectious complications in
       adults. Predominantly CDC IV type patients where included. In an
       intermediate analysis of the trial we screened the clinical reports of
       72 patients in the control group (16 ARC; 56 AIDS) and 76 patients in
       the Venimmun group (14 ARC; 62 AIDS). Observation period ranges from
       4-136 weeks. The two groups were comparable with regard to age and sex.
       Furthermore, there was no difference concerning the transmission of HIV
       in both groups. In addition we TABULAR DATA, SEE ABSTRACT VOLUME. found
       a significant reduction of serious infections and in death due to
       infection in the IVIG group. (8/23 control; 1/16 IVIG; death by
       infection/total death). We conclude at this moment a distinct benefit of
       the IVIG-therapy in HIV-infected adults.
 DE    Acquired Immunodeficiency Syndrome/IMMUNOLOGY/*THERAPY  Adult
       AIDS-Related Complex/IMMUNOLOGY/THERAPY  AIDS-Related Opportunistic
       Infections/EPIDEMIOLOGY/MORTALITY/  *PREVENTION & CONTROL  Body
       Weight/DRUG EFFECTS  Comparative Study  Fever/EPIDEMIOLOGY/PREVENTION &
       CONTROL  Human  Immunoglobulins, Intravenous/*THERAPEUTIC USE  Treatment
       Outcome  CLINICAL TRIAL  MEETING ABSTRACT  RANDOMIZED CONTROLLED TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

